These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34977341)

  • 21. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
    Koopmans I; Hendriks D; Samplonius DF; van Ginkel RJ; Heskamp S; Wierstra PJ; Bremer E; Helfrich W
    Oncoimmunology; 2018; 7(8):e1466016. PubMed ID: 30221065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.
    Mostafa AA; Meyers DE; Thirukkumaran CM; Liu PJ; Gratton K; Spurrell J; Shi Q; Thakur S; Morris DG
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29914097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model.
    Veinalde R; Pidelaserra-Martí G; Moulin C; Tan CL; Schäfer TE; Kang N; Ball CR; Leichsenring J; Stenzinger A; Kaderali L; Jäger D; Ungerechts G; Engeland CE
    Front Immunol; 2022; 13():1096162. PubMed ID: 36726983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.
    Xie X; Lv J; Zhu W; Tian C; Li J; Liu J; Zhou H; Sun C; Hu Z; Li X
    Transl Oncol; 2022 Jan; 15(1):101287. PubMed ID: 34808461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 30. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
    Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
    J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.
    Bernardo M; Tolstykh T; Zhang YA; Bangari DS; Cao H; Heyl KA; Lee JS; Malkova NV; Malley K; Marquez E; Pollard J; Qu H; Roberts E; Ryan S; Singh K; Sun F; Wang E; Bahjat K; Wiederschain D; Wagenaar TR
    Oncoimmunology; 2021 Mar; 10(1):1881268. PubMed ID: 33796402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 34. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
    Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
    Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.
    Liu Z; Ravindranathan R; Kalinski P; Guo ZS; Bartlett DL
    Nat Commun; 2017 Mar; 8():14754. PubMed ID: 28345650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer.
    Wang M; Bai Y; Pei J; Li D; Pu X; Zhu W; Xia L; Qi C; Jiang H; Ning Y
    Front Pharmacol; 2022; 13():887457. PubMed ID: 35548349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic measles virus strains as novel anticancer agents.
    Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
    Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live Attenuated Measles Virus Vaccine Expressing
    Iankov ID; Kurokawa C; Viker K; Robinson SI; Ammayappan A; Panagioti E; Federspiel MJ; Galanis E
    Mol Ther Oncolytics; 2020 Dec; 19():136-148. PubMed ID: 33145397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecules baicalein and cinnamaldehyde are potentiators of measles virus-induced breast cancer oncolysis.
    Kuo YT; Liu CH; Wong SH; Pan YC; Lin LT
    Phytomedicine; 2021 Aug; 89():153611. PubMed ID: 34144429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.